TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Patient-Centered Medication Therapy Management Intervention to Reduce Inappropriate Anticholinergic Prescribing in the Elderly
Brief Summary: This will be an eight-week, prospective, placebo-controlled, randomized trial to evaluate a patient-centered team (pharmacist-physician) intervention to improve medication appropriateness and reduce the use of inappropriate anticholinergic medications in elderly patients enrolled in the Sanders-Brown Alzheimer's Disease Center (ADC) cohort.


Options:
A: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
B: Arm Label: Brain Safe App; Type: EXPERIMENTAL; Interventions: Other: Brain Safe App | Arm Label: Attention Control App; Type: SHAM_COMPARATOR; Interventions: Other: Attention Control App | Intervention Type: OTHER; Name: Brain Safe App; Assigned to Arm(s): Brain Safe App | Intervention Type: OTHER; Name: Attention Control App; Assigned to Arm(s): Attention Control App
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Mirabegron; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1 - Intervention; Type: EXPERIMENTAL; Interventions: Other: Arm 1 Education Session | Arm Label: Arm 2 - Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Arm 1 Education Session; Assigned to Arm(s): Arm 1 - Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study on the Effectiveness of Occupational Therapy Intervention in Complex Patients.
Brief Summary: To date, there are no studies that demonstrate that the intervention of Occupational Therapy (OT) in patients considered to be complex, regardless of diagnosis, could improve clinical and functional outcome for the patient.

For this reason, we intend to undertake a study that will allow us to deepen the knowledge about the impact of the OT on in-hospital patients considered "complex" according to the assessment by the Rehabilitation Complexity Scale (RCS ).

Our hypothesis is that the intervention of OT can improve their care by qualified and focused on the needs of the person interventions.


Options:
A: Arm Label: attention training acute; Type: EXPERIMENTAL; Interventions: Behavioral: APT training, Behavioral: Multiprofessional rehabilitation | Arm Label: attention training subacute; Type: EXPERIMENTAL; Interventions: Behavioral: APT training, Behavioral: Multiprofessional rehabilitation | Intervention Type: BEHAVIORAL; Name: APT training; Assigned to Arm(s): attention training acute, attention training subacute | Intervention Type: BEHAVIORAL; Name: Multiprofessional rehabilitation; Assigned to Arm(s): attention training acute, attention training subacute
B: Arm Label: Guttmann, NeuroPersonalTrainer; Type: EXPERIMENTAL; Interventions: Other: Guttmann, NeuroPersonalTrainer | Arm Label: Ictus.online; Type: SHAM_COMPARATOR; Interventions: Other: Ictus.online | Intervention Type: OTHER; Name: Guttmann, NeuroPersonalTrainer; Assigned to Arm(s): Guttmann, NeuroPersonalTrainer | Intervention Type: OTHER; Name: Ictus.online; Assigned to Arm(s): Ictus.online
C: Arm Label: OT arm; Type: N/A; Interventions: N/A
D: Arm Label: Robot group; Type: EXPERIMENTAL; Interventions: Device: robot-assisted neurocognitive therapy of hand function | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional neurocognitive rehabilitation | Intervention Type: DEVICE; Name: robot-assisted neurocognitive therapy of hand function; Assigned to Arm(s): Robot group | Intervention Type: OTHER; Name: Conventional neurocognitive rehabilitation; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study
Brief Summary: A prospective randomized study on Safety, Tolerability and Efficacy of oral Low dose DFP (50 mg/kg/day) in minimally transfused B-TM after 5 transfusions when SF reaches 500 ng/m and with either appearance of LPI \> 0.2 or TSAT reaches 50% compared with non treatment arm.

So the aim of this study:

1. To determine the time as well as amount of transfused iron ( calculated in mg iron/kg ) which lead to Serum ferritin reaches 500 ng /ml and LPI appearance \>0.2 as well as TSAT reaches 50 % .
2. Tolerability and safety of early low dose DFP 50mg/kg and effectiveness to postpone or prevent SF from reaching 1000 ng/ml or LPI \>0.6 or TSAT \>70% in comparison to patients not starting chelation therapy
3. Determine adverse events whether drug or non drug related


Options:
A: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
B: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
C: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
D: Arm Label: arm 1 iron chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone | Arm Label: arm 2 blood transfusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Deferiprone | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): arm 1 iron chelation, arm 2 blood transfusion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Medication Adherence in Older African Americans With Diabetes
Brief Summary: This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes. This may preserve their independence and health, prevent cognitive and functional decline, and reduce health care costs. As the population ages and becomes more racially diverse, finding ways to achieve these outcomes has great public health importance.


Options:
A: Arm Label: Mobile Insulin Titration Intervention; Type: EXPERIMENTAL; Interventions: Other: Mobile Insulin Titration Intervention | Arm Label: Current Best Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Insulin Titration Intervention; Assigned to Arm(s): Mobile Insulin Titration Intervention
B: Arm Label: Primary Care-Occupational Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Primary Care-Occupational Therapy | Arm Label: Enhanced Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Primary Care-Occupational Therapy; Assigned to Arm(s): Primary Care-Occupational Therapy | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: Feedback report only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Goal-Setting Worksheet; Type: EXPERIMENTAL; Interventions: Other: Worksheet to facilitate goal-setting and action plans | Intervention Type: OTHER; Name: Worksheet to facilitate goal-setting and action plans; Assigned to Arm(s): Goal-Setting Worksheet
D: Arm Label: The Education Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: The Education Health Program | Intervention Type: BEHAVIORAL; Name: The Education Health Program; Assigned to Arm(s): The Education Health Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Brief Summary: The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis


Options:
A: Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Arm Label: Epoetin Injection; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Injection
B: Arm Label: MT-6548; Type: EXPERIMENTAL; Interventions: Drug: MT-6548 | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: MT-6548; Assigned to Arm(s): MT-6548 | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.


Options:
A: Arm Label: Vadadustat once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat three times weekly (TIW); Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat once daily (QD), Vadadustat three times weekly (TIW) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: Arm A + E (Participants on HD): Roxadustat Only, No Iron; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Arm Label: Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: IV Iron | Arm Label: Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Arm A + E (Participants on HD): Roxadustat Only, No Iron, Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: Oral Iron; Assigned to Arm(s): Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg
C: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Epoetin alfa
D: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care.
Brief Summary: A randomized controlled trial of a texting intervention to increase adherence to preventative asthma medication in four Cincinnati Children's Hospital Medical Center primary care clinics.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: Text Messaging | Intervention Type: BEHAVIORAL; Name: Text Messaging; Assigned to Arm(s): Text Messaging
B: Arm Label: School-based Telemedicine Enhanced Asthma Mangement Group; Type: EXPERIMENTAL; Interventions: Other: School-Based Telemedicine Enhanced Asthma Management | Arm Label: Enhanced Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: School-Based Telemedicine Enhanced Asthma Management; Assigned to Arm(s): School-based Telemedicine Enhanced Asthma Mangement Group | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care Group
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Spencer | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spencer; Assigned to Arm(s): Intervention group
D: Arm Label: Case Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: Other: MyMediHealth access | Intervention Type: OTHER; Name: MyMediHealth access; Assigned to Arm(s): Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Podiatry Intervention to Reduce Falls in Care Home Residents: Development, Feasibility and Acceptability Study With Exploratory Randomised Controlled Trial
Brief Summary: This is an exploratory pilot Randomised Controlled Trial (RCT) to investigate the effects of a multifaceted podiatry intervention designed to reduce falls in care homes. The investigators hypothesise that the intervention will reduce the high falls rates present in care homes for older people, compared to usual care.

The results will inform the sample size calculation for a full-scale definitive RCT


Options:
A: Arm Label: Active Medication Group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous zoledronic acid, Dietary Supplement: Vitamin D 800 IU/daily, Dietary Supplement: Calcium 1200 mg/daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous zoledronic acid, Dietary Supplement: Vitamin D 800 IU/daily, Dietary Supplement: Calcium 1200 mg/daily | Intervention Type: DRUG; Name: Intravenous zoledronic acid; Assigned to Arm(s): Active Medication Group, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 800 IU/daily; Assigned to Arm(s): Active Medication Group, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium 1200 mg/daily; Assigned to Arm(s): Active Medication Group, Placebo
B: Intervention Type: DEVICE; Name: BedEx Patient Occupancy Monitoring System; Assigned to Arm(s): N/A
C: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit
D: Arm Label: Mulitfaceted podiatry Intervention; Type: EXPERIMENTAL; Interventions: Other: Foot and ankle exercises, foot orthoses, footwear provision | Arm Label: Usual podiatry care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Foot and ankle exercises, foot orthoses, footwear provision; Assigned to Arm(s): Mulitfaceted podiatry Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual podiatry care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke. A Phase II, Open-label, Multicenter, Randomized and Controlled Clinical Trial.
Brief Summary: This trial aims to test that intra-arterial injection of autologous bone marrow mononuclear cells in acute ischemic stroke patients is safe and improves neurological outcomes.


Options:
A: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell
B: Arm Label: Mesenchymal stem cell treatment; Type: EXPERIMENTAL; Interventions: Other: Mesenchymal stem cell | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment
C: Arm Label: Bone marrow transplantation low dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Bone marrow transplantation high dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Autologous bone marrow mononuclear cell intra-arterial injection; Assigned to Arm(s): Bone marrow transplantation high dose, Bone marrow transplantation low dose
D: Arm Label: SB623 Implant (2.5M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (5.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (10.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Intervention Type: BIOLOGICAL; Name: SB623; Assigned to Arm(s): SB623 Implant (10.0M), SB623 Implant (2.5M), SB623 Implant (5.0M)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents
Brief Summary: Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective vaccine is a global health priority.

Over a billion people worldwide are infected with one or more helminths. Helminths are parasitic worms, of which Schistosoma mansoni is one species. There is some evidence that helminth infection may affect a person's response to a vaccine. In this trial the investigators hope to investigate whether Schistosoma mansoni infection affects adolescents' responses to a candidate TB vaccine called MVA85A, as adolescents are a crucial target group for an effective TB vaccine.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: BCG | Intervention Type: BIOLOGICAL; Name: BCG; Assigned to Arm(s): 1
D: Intervention Type: BIOLOGICAL; Name: MVA85A (Tuberculosis vaccine); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HealthMap: a Cluster Randomised Trial of Interactive Health Plans and Self-management Support to Prevent Cardiovascular Disease in People With HIV
Brief Summary: The purpose of this study is to improve the health status of people living with HIV in Australia. The overall goal is to rigorously evaluate the impact of interactive health plans and self-management support on chronic condition outcomes in people with HIV.

The specific aims are to:

Aim 1: Using a doctor-level cluster randomised trial, evaluate the effect of interactive health plans and self-management support on coronary heart disease risk and other chronic condition outcomes in people living with HIV.

Aim 2: Evaluate patient and health care provider experiences and acceptability of interactive health plans and self-management support.

Aim 3: Evaluate intervention cost-effectiveness and effect on health service utilisation.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
B: Arm Label: Online disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Online disease management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Online disease management; Assigned to Arm(s): Online disease management
C: Arm Label: Integrated self management support; Type: OTHER; Interventions: Other: Integrated self management support | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated self management support; Assigned to Arm(s): Integrated self management support
D: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A

Answer: C